{"transactions":[{"id":4628867,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-10-02T22:14:40.000Z","date":"2026-09-30","kind":"exercise","planned":false,"acquired":false,"shares":9801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":83602,"derivative":{"underlying":"Common Stock","underlying_shares":9801},"source":{"system":"sec-edgar","filing":"0001437749-26-031925","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031925/rdgdoc.xml","form_type":"4"}},{"id":4628866,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T22:14:40.000Z","date":"2026-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":4344,"price":79.67,"value":346086.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":104724,"source":{"system":"sec-edgar","filing":"0001437749-26-031925","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031925/rdgdoc.xml","form_type":"4"}},{"id":4628865,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T22:14:40.000Z","date":"2026-09-30","kind":"exercise","planned":false,"acquired":true,"shares":9801,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":109068,"source":{"system":"sec-edgar","filing":"0001437749-26-031925","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031925/rdgdoc.xml","form_type":"4"}},{"id":4627958,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter."}],"balance_after":27204,"derivative":{"exercise_price":14,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":4627957,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"exercise","planned":true,"acquired":false,"shares":14056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter."}],"balance_after":15044,"derivative":{"exercise_price":30,"expiration_date":"2028-08-08","underlying":"Common Stock","underlying_shares":14056},"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":4627956,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"sale","planned":true,"acquired":false,"shares":600,"price":89.79,"value":53874.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4."}],"balance_after":99267,"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":4627955,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"sale","planned":true,"acquired":false,"shares":8368,"price":88.97,"value":744500.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4."}],"balance_after":99867,"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":4627954,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"sale","planned":true,"acquired":false,"shares":9638,"price":87.96,"value":847758.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4."}],"balance_after":108235,"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":4627953,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"sale","planned":true,"acquired":false,"shares":10450,"price":87.15,"value":910717.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4."}],"balance_after":117873,"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":4627952,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":14,"value":210000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."}],"balance_after":128323,"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":4627951,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-29T00:47:40.000Z","date":"2026-09-24","kind":"exercise","planned":true,"acquired":true,"shares":14056,"price":30,"value":421680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026."}],"balance_after":113323,"source":{"system":"sec-edgar","filing":"0001437749-26-031411","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727334/000143774926031411/rdgdoc.xml","form_type":"4"}},{"id":717151,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-07-02T23:38:00.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":false,"shares":12873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":93403,"derivative":{"underlying":"Common Stock","underlying_shares":12873},"source":{"system":"sec-edgar","filing":"0001437749-26-022630","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926022630/rdgdoc.xml","form_type":"4"}},{"id":717150,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T23:38:00.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":4084,"price":92.59,"value":378137.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":99267,"source":{"system":"sec-edgar","filing":"0001437749-26-022630","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926022630/rdgdoc.xml","form_type":"4"}},{"id":717149,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T23:38:00.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":true,"shares":12873,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":103351,"source":{"system":"sec-edgar","filing":"0001437749-26-022630","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926022630/rdgdoc.xml","form_type":"4"}},{"id":818857,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-02T19:03:36.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":false,"shares":6732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":106276,"derivative":{"underlying":"Common Stock","underlying_shares":6732},"source":{"system":"sec-edgar","filing":"0001437749-26-011079","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926011079/rdgdoc.xml","form_type":"4"}},{"id":818856,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-02T19:03:36.000Z","date":"2026-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1972,"price":54.79,"value":108045.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":90478,"source":{"system":"sec-edgar","filing":"0001437749-26-011079","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926011079/rdgdoc.xml","form_type":"4"}},{"id":818855,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-02T19:03:36.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":true,"shares":6732,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":92450,"source":{"system":"sec-edgar","filing":"0001437749-26-011079","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926011079/rdgdoc.xml","form_type":"4"}},{"id":926758,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-30T19:31:04.000Z","date":"2025-01-28","kind":"other","planned":false,"acquired":true,"shares":62815,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata liquidating distribution from Tactic Pharma, LLC (\"Tactic\"), of which the reporting person is a non-controlling member. In prior reports, the reporting person reported beneficial ownership of 272,026 shares of Monopar Therapeutics Inc. common stock held by Tactic."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020."}],"balance_after":62815,"source":{"system":"sec-edgar","filing":"0001437749-26-002527","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926002527/rdgdoc.xml","form_type":"4"}},{"id":949918,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-05T20:46:21.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":8724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":113008,"derivative":{"underlying":"Common Stock","underlying_shares":8724},"source":{"system":"sec-edgar","filing":"0001437749-26-000306","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926000306/rdgdoc.xml","form_type":"4"}},{"id":949917,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-05T20:46:21.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":2558,"price":65.3,"value":167037.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":85718,"source":{"system":"sec-edgar","filing":"0001437749-26-000306","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926000306/rdgdoc.xml","form_type":"4"}},{"id":949916,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-05T20:46:21.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":8724,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":88276,"source":{"system":"sec-edgar","filing":"0001437749-26-000306","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926000306/rdgdoc.xml","form_type":"4"}},{"id":977291,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-08T21:46:34.000Z","date":"2025-12-02","kind":"grant","planned":false,"acquired":true,"shares":49133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter."}],"balance_after":121732,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":49133},"source":{"system":"sec-edgar","filing":"0001437749-25-037163","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925037163/rdgdoc.xml","form_type":"4"}},{"id":977290,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2025-12-08T21:46:34.000Z","date":"2025-12-02","kind":"grant","planned":false,"acquired":true,"shares":16753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2026, and 1/48th per month thereafter."}],"balance_after":16753,"derivative":{"exercise_price":75.94,"expiration_date":"2035-12-02","underlying":"Common Stock","underlying_shares":16753},"source":{"system":"sec-edgar","filing":"0001437749-25-037163","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925037163/rdgdoc.xml","form_type":"4"}},{"id":1026481,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-02T19:04:01.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":false,"shares":8726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":72599,"derivative":{"underlying":"Common Stock","underlying_shares":8726},"source":{"system":"sec-edgar","filing":"0001437749-25-030284","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925030284/rdgdoc.xml","form_type":"4"}},{"id":1026480,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T19:04:01.000Z","date":"2025-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2646,"price":81.67,"value":216098.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":79552,"source":{"system":"sec-edgar","filing":"0001437749-25-030284","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925030284/rdgdoc.xml","form_type":"4"}},{"id":1026479,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T19:04:01.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":true,"shares":8726,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":82198,"source":{"system":"sec-edgar","filing":"0001437749-25-030284","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925030284/rdgdoc.xml","form_type":"4"}},{"id":1031885,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"ten_percent_owner":true}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":2,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}},{"id":64053,"kind":"person","name":"Brown Michael J","position":3,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":5,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}}],"security":"Common Stock","published_at":"2025-09-26T15:53:30.000Z","date":"2025-09-24","kind":"sale","planned":false,"acquired":false,"shares":550229,"price":63.6098,"value":34999956.6442,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc."}],"balance_after":272026,"source":{"system":"sec-edgar","filing":"0001437749-25-029925","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000143774925029925/rdgdoc.xml","form_type":"4"}},{"id":1086344,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2025-07-17T01:02:07.000Z","date":"2025-07-14","kind":"other","planned":false,"acquired":false,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Robinson on February 20, 2017, for his services as a director and officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter."}],"balance_after":0,"derivative":{"exercise_price":0.005,"expiration_date":"2027-02-20","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001437749-25-022861","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925022861/rdgdoc.xml","form_type":"4"}},{"id":1086343,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-17T01:02:07.000Z","date":"2025-07-14","kind":"sale","planned":false,"acquired":false,"shares":16800,"price":40.0012,"value":672020.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":73472,"source":{"system":"sec-edgar","filing":"0001437749-25-022861","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925022861/rdgdoc.xml","form_type":"4"}},{"id":1086342,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-17T01:02:07.000Z","date":"2025-07-14","kind":"other","planned":false,"acquired":true,"shares":16800,"price":0.005,"value":84.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a cash exercise of stock options."}],"balance_after":90272,"source":{"system":"sec-edgar","filing":"0001437749-25-022861","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925022861/rdgdoc.xml","form_type":"4"}},{"id":1094182,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-02T20:25:14.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":false,"shares":13344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":81325,"derivative":{"underlying":"Common Stock","underlying_shares":13344},"source":{"system":"sec-edgar","filing":"0001437749-25-021994","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925021994/rdgdoc.xml","form_type":"4"}},{"id":1094181,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-02T20:25:14.000Z","date":"2025-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":5865,"price":35.78,"value":209849.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":73472,"source":{"system":"sec-edgar","filing":"0001437749-25-021994","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925021994/rdgdoc.xml","form_type":"4"}},{"id":1094180,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-02T20:25:14.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":true,"shares":13344,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":79337,"source":{"system":"sec-edgar","filing":"0001437749-25-021994","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925021994/rdgdoc.xml","form_type":"4"}},{"id":1177879,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":74939,"kind":"organization","name":"Tactic Pharma LLC","position":1,"cik":"0001727357","reported_name":"Tactic Pharma LLC","relationship":{"ten_percent_owner":true}},{"id":32623,"kind":"person","name":"Robinson Chandler","position":2,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}},{"id":64053,"kind":"person","name":"Brown Michael J","position":3,"cik":"0001035909","reported_name":"Brown Michael J","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":74940,"kind":"person","name":"O'Halloran Thomas V.","position":4,"cik":"0001727481","reported_name":"O'Halloran Thomas V.","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}},{"id":54676,"kind":"person","name":"Mazar Andrew Paul","position":5,"cik":"0001727393","reported_name":"Mazar Andrew Paul","relationship":{"other":true,"other_text":"Member of 10% Owner Group"}}],"security":"Common Stock","published_at":"2025-04-04T19:27:32.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":33334,"price":35,"value":1166690.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.86, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company (\"Tactic\"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the \"Reporting Persons\"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein."}],"balance_after":822255,"source":{"system":"sec-edgar","filing":"0001437749-25-011068","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035909/000143774925011068/rdgdoc.xml","form_type":"4"}},{"id":1182468,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-03T01:07:37.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":false,"shares":4106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":94669,"derivative":{"underlying":"Common Stock","underlying_shares":4106},"source":{"system":"sec-edgar","filing":"0001437749-25-010809","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925010809/rdgdoc.xml","form_type":"4"}},{"id":1182467,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-03T01:07:37.000Z","date":"2025-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1204,"price":36.41,"value":43837.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":65993,"source":{"system":"sec-edgar","filing":"0001437749-25-010809","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925010809/rdgdoc.xml","form_type":"4"}},{"id":1182466,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-03T01:07:37.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":4106,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":67197,"source":{"system":"sec-edgar","filing":"0001437749-25-010809","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925010809/rdgdoc.xml","form_type":"4"}},{"id":1216832,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-08T02:24:31.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":6002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":98775,"derivative":{"underlying":"Common Stock","underlying_shares":6002},"source":{"system":"sec-edgar","filing":"0001437749-25-006736","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925006736/rdgdoc.xml","form_type":"4"}},{"id":1216831,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-08T02:24:31.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":79899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter."}],"balance_after":104777,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":79899},"source":{"system":"sec-edgar","filing":"0001437749-25-006736","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925006736/rdgdoc.xml","form_type":"4"}},{"id":1216830,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2025-03-08T02:24:31.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":85759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"6,647 options vested on the grant date. Remainder of options vest 6/48ths on June 30, 2025, and 1/48th per month thereafter."}],"balance_after":85759,"derivative":{"exercise_price":31.7,"expiration_date":"2035-03-04","underlying":"Common Stock","underlying_shares":85759},"source":{"system":"sec-edgar","filing":"0001437749-25-006736","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925006736/rdgdoc.xml","form_type":"4"}},{"id":1216829,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-08T02:24:31.000Z","date":"2025-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":1759,"price":31.7,"value":55760.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":63091,"source":{"system":"sec-edgar","filing":"0001437749-25-006736","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925006736/rdgdoc.xml","form_type":"4"}},{"id":1216828,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-08T02:24:31.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":6002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":64850,"source":{"system":"sec-edgar","filing":"0001437749-25-006736","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925006736/rdgdoc.xml","form_type":"4"}},{"id":1318263,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-02T23:14:58.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":4895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":24879,"derivative":{"underlying":"Common Stock","underlying_shares":4895},"source":{"system":"sec-edgar","filing":"0001437749-25-000096","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925000096/rdgdoc.xml","form_type":"4"}},{"id":1318262,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-02T23:14:58.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":2209,"price":22,"value":48598.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":58848,"source":{"system":"sec-edgar","filing":"0001437749-25-000096","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925000096/rdgdoc.xml","form_type":"4"}},{"id":1318261,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-02T23:14:58.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":4895,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":61057,"source":{"system":"sec-edgar","filing":"0001437749-25-000096","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925000096/rdgdoc.xml","form_type":"4"}},{"id":1393681,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-02T23:45:42.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":4895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":29774,"derivative":{"underlying":"Common Stock","underlying_shares":4895},"source":{"system":"sec-edgar","filing":"0001437749-24-030536","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924030536/rdgdoc.xml","form_type":"4"}},{"id":1393680,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-02T23:45:42.000Z","date":"2024-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":1918,"price":6.74,"value":12927.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":56162,"source":{"system":"sec-edgar","filing":"0001437749-24-030536","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924030536/rdgdoc.xml","form_type":"4"}},{"id":1393679,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-02T23:45:42.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":4895,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":58080,"source":{"system":"sec-edgar","filing":"0001437749-24-030536","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924030536/rdgdoc.xml","form_type":"4"}},{"id":1462044,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-02T22:07:08.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":false,"shares":24476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":173335,"derivative":{"underlying":"Common Stock","underlying_shares":24476},"source":{"system":"sec-edgar","filing":"0001437749-24-022023","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924022023/rdgdoc.xml","form_type":"4"}},{"id":1462043,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-02T22:07:08.000Z","date":"2024-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":8684,"price":0.731,"value":6348.004,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":265922.8,"source":{"system":"sec-edgar","filing":"0001437749-24-022023","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924022023/rdgdoc.xml","form_type":"4"}},{"id":1462042,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-02T22:07:08.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":true,"shares":24476,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":274606.8,"source":{"system":"sec-edgar","filing":"0001437749-24-022023","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924022023/rdgdoc.xml","form_type":"4"}},{"id":1497465,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2024-05-30T22:10:53.000Z","date":"2024-05-28","kind":"other","planned":false,"acquired":false,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects options to purchase up to 84,000 shares of common stock granted to Dr. Robinson on April 4, 2016 for his services as a director and officer of Monopar Therapeutics. The options vested 50% upon grant date, 25% upon the 6-month anniversary of grant date, and 25% upon the 1-year anniversary of grant date."}],"balance_after":0,"derivative":{"exercise_price":0.001,"expiration_date":"2026-04-03","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001437749-24-018775","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924018775/rdgdoc.xml","form_type":"4"}},{"id":1497464,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-30T22:10:53.000Z","date":"2024-05-28","kind":"other","planned":false,"acquired":true,"shares":84000,"price":0.001,"value":84.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":250130.8,"source":{"system":"sec-edgar","filing":"0001437749-24-018775","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924018775/rdgdoc.xml","form_type":"4"}},{"id":1552629,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-03T00:33:00.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":24474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":197811,"derivative":{"underlying":"Common Stock","underlying_shares":24474},"source":{"system":"sec-edgar","filing":"0001437749-24-010721","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924010721/rdgdoc.xml","form_type":"4"}},{"id":1552628,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-03T00:33:00.000Z","date":"2024-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":7172,"price":0.681,"value":4884.132,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":166130.8,"source":{"system":"sec-edgar","filing":"0001437749-24-010721","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924010721/rdgdoc.xml","form_type":"4"}},{"id":1552627,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-03T00:33:00.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":24474,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":173302.8,"source":{"system":"sec-edgar","filing":"0001437749-24-010721","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924010721/rdgdoc.xml","form_type":"4"}},{"id":1690759,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-04T00:36:00.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":6724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":222285,"derivative":{"underlying":"Common Stock","underlying_shares":6724},"source":{"system":"sec-edgar","filing":"0001437749-24-000482","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924000482/rdgdoc.xml","form_type":"4"}},{"id":1690758,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-04T00:36:00.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":24474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":229009,"derivative":{"underlying":"Common Stock","underlying_shares":24474},"source":{"system":"sec-edgar","filing":"0001437749-24-000482","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924000482/rdgdoc.xml","form_type":"4"}},{"id":1690757,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T00:36:00.000Z","date":"2024-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2327,"price":0.3402,"value":791.6454,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":148828.8,"source":{"system":"sec-edgar","filing":"0001437749-24-000482","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924000482/rdgdoc.xml","form_type":"4"}},{"id":1690756,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T00:36:00.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":6724,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":151155.8,"source":{"system":"sec-edgar","filing":"0001437749-24-000482","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924000482/rdgdoc.xml","form_type":"4"}},{"id":1690755,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T00:36:00.000Z","date":"2023-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":8469,"price":0.3402,"value":2881.1538,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":144431.8,"source":{"system":"sec-edgar","filing":"0001437749-24-000482","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924000482/rdgdoc.xml","form_type":"4"}},{"id":1690754,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T00:36:00.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":24474,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":152900.8,"source":{"system":"sec-edgar","filing":"0001437749-24-000482","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924000482/rdgdoc.xml","form_type":"4"}},{"id":1766515,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-03T23:37:11.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":false,"shares":24474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":253483,"derivative":{"underlying":"Common Stock","underlying_shares":24474},"source":{"system":"sec-edgar","filing":"0001437749-23-027588","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923027588/rdgdoc.xml","form_type":"4"}},{"id":1766514,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-03T23:37:11.000Z","date":"2023-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":7172,"price":0.6199,"value":4445.9228,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":128426.8,"source":{"system":"sec-edgar","filing":"0001437749-23-027588","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923027588/rdgdoc.xml","form_type":"4"}},{"id":1766513,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-03T23:37:11.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":true,"shares":24474,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":135598.8,"source":{"system":"sec-edgar","filing":"0001437749-23-027588","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923027588/rdgdoc.xml","form_type":"4"}},{"id":1839261,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-03T22:45:33.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":false,"shares":35039,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":277957,"derivative":{"underlying":"Common Stock","underlying_shares":35039},"source":{"system":"sec-edgar","filing":"0001437749-23-019257","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923019257/rdgdoc.xml","form_type":"4"}},{"id":1839260,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-03T22:45:33.000Z","date":"2023-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":10269,"price":0.855,"value":8779.995,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":111124.8,"source":{"system":"sec-edgar","filing":"0001437749-23-019257","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923019257/rdgdoc.xml","form_type":"4"}},{"id":1839259,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-03T22:45:33.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":true,"shares":35039,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":121393.8,"source":{"system":"sec-edgar","filing":"0001437749-23-019257","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923019257/rdgdoc.xml","form_type":"4"}},{"id":1926692,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-04T21:17:20.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":false,"shares":13911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":312996,"derivative":{"underlying":"Common Stock","underlying_shares":13911},"source":{"system":"sec-edgar","filing":"0001437749-23-009332","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923009332/rdgdoc.xml","form_type":"4"}},{"id":1926691,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-04T21:17:20.000Z","date":"2023-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4286,"price":1.39,"value":5957.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":86354.8,"source":{"system":"sec-edgar","filing":"0001437749-23-009332","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923009332/rdgdoc.xml","form_type":"4"}},{"id":1926690,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-04T21:17:20.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":true,"shares":13911,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":90640.8,"source":{"system":"sec-edgar","filing":"0001437749-23-009332","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923009332/rdgdoc.xml","form_type":"4"}},{"id":2032029,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T23:49:37.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":169012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026)"}],"balance_after":326907,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169012},"source":{"system":"sec-edgar","filing":"0001437749-23-002518","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923002518/rdgdoc.xml","form_type":"4"}},{"id":2032028,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2023-02-03T23:49:37.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":221839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2023 and 1/48th per month thereafter."}],"balance_after":221839,"derivative":{"exercise_price":3.16,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":221839},"source":{"system":"sec-edgar","filing":"0001437749-23-002518","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923002518/rdgdoc.xml","form_type":"4"}},{"id":2072079,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-03T20:59:47.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":6723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On January 31, 2020, the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On January 31, 2020, the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":6724,"derivative":{"underlying":"Common Stock","underlying_shares":6723},"source":{"system":"sec-edgar","filing":"0001437749-23-000160","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923000160/rdgdoc.xml","form_type":"4"}},{"id":2072078,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-03T20:59:47.000Z","date":"2022-12-31","kind":"exercise","acquired":false,"shares":13912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":151171,"derivative":{"underlying":"Common Stock","underlying_shares":13912},"source":{"system":"sec-edgar","filing":"0001437749-23-000160","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923000160/rdgdoc.xml","form_type":"4"}},{"id":2072077,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-03T20:59:47.000Z","date":"2023-01-01","kind":"tax_withholding","acquired":false,"shares":2327,"price":2.37,"value":5514.99,"ownership":{"direct":true},"balance_after":76729.8,"source":{"system":"sec-edgar","filing":"0001437749-23-000160","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923000160/rdgdoc.xml","form_type":"4"}},{"id":2072076,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-03T20:59:47.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":6723,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":79056.8,"source":{"system":"sec-edgar","filing":"0001437749-23-000160","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923000160/rdgdoc.xml","form_type":"4"}},{"id":2072075,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-03T20:59:47.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":false,"shares":4814,"price":2.37,"value":11409.18,"ownership":{"direct":true},"balance_after":72333.8,"source":{"system":"sec-edgar","filing":"0001437749-23-000160","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923000160/rdgdoc.xml","form_type":"4"}},{"id":2072074,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-03T20:59:47.000Z","date":"2022-12-31","kind":"exercise","acquired":true,"shares":13912,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":77147.8,"source":{"system":"sec-edgar","filing":"0001437749-23-000160","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923000160/rdgdoc.xml","form_type":"4"}},{"id":2146951,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-03T23:55:19.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":13911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 2, 2022,  the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 2, 2022,  the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":178530,"derivative":{"underlying":"Common Stock","underlying_shares":13911},"source":{"system":"sec-edgar","filing":"0001654954-22-013280","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422013280/section16.xml","form_type":"4"}},{"id":2146950,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-03T23:55:19.000Z","date":"2022-09-30","kind":"tax_withholding","acquired":false,"shares":4077,"price":1.52,"value":6197.04,"ownership":{"direct":true},"balance_after":63235.8,"source":{"system":"sec-edgar","filing":"0001654954-22-013280","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422013280/section16.xml","form_type":"4"}},{"id":2146949,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-03T23:55:19.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":13911,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":67312.8,"source":{"system":"sec-edgar","filing":"0001654954-22-013280","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422013280/section16.xml","form_type":"4"}},{"id":2216717,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-07-01T20:07:39.000Z","date":"2022-06-30","kind":"exercise","acquired":false,"shares":23882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 2, 2022,  the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 2, 2022,  the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":192441,"derivative":{"underlying":"Common Stock","underlying_shares":23882},"source":{"system":"sec-edgar","filing":"0001654954-22-009138","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422009138/section16.xml","form_type":"4"}},{"id":2216716,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-01T20:07:39.000Z","date":"2022-06-30","kind":"tax_withholding","acquired":false,"shares":6999,"price":2.299,"value":16090.701,"ownership":{"direct":true},"balance_after":53401.8,"source":{"system":"sec-edgar","filing":"0001654954-22-009138","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422009138/section16.xml","form_type":"4"}},{"id":2216715,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-01T20:07:39.000Z","date":"2022-06-30","kind":"exercise","acquired":true,"shares":23882,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":60400.8,"source":{"system":"sec-edgar","filing":"0001654954-22-009138","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422009138/section16.xml","form_type":"4"}},{"id":2310693,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-04-01T21:28:37.000Z","date":"2022-03-31","kind":"exercise","acquired":false,"shares":3941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":216323,"derivative":{"underlying":"Common Stock","underlying_shares":3941},"source":{"system":"sec-edgar","filing":"0001654954-22-004491","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422004491/section16.xml","form_type":"4"}},{"id":2310692,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-01T21:28:37.000Z","date":"2022-03-31","kind":"tax_withholding","acquired":false,"shares":1155,"price":2.55,"value":2945.25,"ownership":{"direct":true},"balance_after":36518.8,"source":{"system":"sec-edgar","filing":"0001654954-22-004491","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422004491/section16.xml","form_type":"4"}},{"id":2310691,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-01T21:28:37.000Z","date":"2022-03-31","kind":"exercise","acquired":true,"shares":3941,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":37673.8,"source":{"system":"sec-edgar","filing":"0001654954-22-004491","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422004491/section16.xml","form_type":"4"}},{"id":2411318,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-05T00:37:56.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":159522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)"}],"balance_after":220264,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":159522},"source":{"system":"sec-edgar","filing":"0001654954-22-001173","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422001173/section16.xml","form_type":"4"}},{"id":2411317,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2022-02-05T00:37:56.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":211018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter."}],"balance_after":211018,"derivative":{"exercise_price":2.8,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":211018},"source":{"system":"sec-edgar","filing":"0001654954-22-001173","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422001173/section16.xml","form_type":"4"}},{"id":2447234,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-04T19:17:38.000Z","date":"2022-01-01","kind":"exercise","acquired":false,"shares":6724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":13447,"derivative":{"underlying":"Common Stock","underlying_shares":6724},"source":{"system":"sec-edgar","filing":"0001654954-22-000126","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000126/section16.xml","form_type":"4"}},{"id":2447233,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:17:38.000Z","date":"2022-01-01","kind":"tax_withholding","acquired":false,"shares":2327,"price":3.21,"value":7469.67,"ownership":{"direct":true},"balance_after":33732.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000126","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000126/section16.xml","form_type":"4"}},{"id":2447232,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:17:38.000Z","date":"2022-01-01","kind":"exercise","acquired":true,"shares":6724,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":36059.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000126","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000126/section16.xml","form_type":"4"}},{"id":2447237,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-04T19:07:31.000Z","date":"2021-12-31","kind":"exercise","acquired":false,"shares":3941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":47295,"derivative":{"underlying":"Common Stock","underlying_shares":3941},"source":{"system":"sec-edgar","filing":"0001654954-22-000124","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000124/section16.xml","form_type":"4"}},{"id":2447236,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:07:31.000Z","date":"2021-12-31","kind":"tax_withholding","acquired":false,"shares":1364,"price":3.21,"value":4378.44,"ownership":{"direct":true},"balance_after":29335.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000124","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000124/section16.xml","form_type":"4"}},{"id":2447235,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-04T19:07:31.000Z","date":"2021-12-31","kind":"exercise","acquired":true,"shares":3941,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":30699.8,"source":{"system":"sec-edgar","filing":"0001654954-22-000124","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422000124/section16.xml","form_type":"4"}},{"id":2553845,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-01T23:24:58.000Z","date":"2021-09-30","kind":"exercise","acquired":false,"shares":3941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":51236,"derivative":{"underlying":"Common Stock","underlying_shares":3941},"source":{"system":"sec-edgar","filing":"0001654954-21-010715","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421010715/section16.xml","form_type":"4"}},{"id":2553844,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-01T23:24:58.000Z","date":"2021-09-30","kind":"tax_withholding","acquired":false,"shares":1155,"price":4.87,"value":5624.85,"ownership":{"direct":true},"balance_after":26758.8,"source":{"system":"sec-edgar","filing":"0001654954-21-010715","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421010715/section16.xml","form_type":"4"}},{"id":2553843,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-01T23:24:58.000Z","date":"2021-09-30","kind":"exercise","acquired":true,"shares":3941,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":27913.8,"source":{"system":"sec-edgar","filing":"0001654954-21-010715","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421010715/section16.xml","form_type":"4"}},{"id":2643544,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32623,"kind":"person","name":"Robinson Chandler","position":1,"cik":"0001727334","reported_name":"Robinson Chandler","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2021-07-02T21:10:01.000Z","date":"2021-06-30","kind":"exercise","acquired":false,"shares":7883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":55177,"derivative":{"underlying":"Common Stock","underlying_shares":7883},"source":{"system":"sec-edgar","filing":"0001654954-21-007593","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495421007593/section16.xml","form_type":"4"}}],"next_cursor":"2021-07-02T21:10:01.000000Z,2643544"}